BillionToOne, Inc. has transitioned from a research-focused firm to a commercial-stage molecular diagnostics company, anchored by its patented smNGS platform achieving single-molecule sensitivity. Its UNITY prenatal test suite provides comprehensive non-invasive fetal genetic risk screening, while the Northstar oncology products deliver superior liquid biopsy capabilities. The company swung to profitability in 2025 with $16 million in operating income and positive free cash flow, driven by increased reimbursement coverage and test volumes. Future growth hinges on further payor network expansion, clinical guideline incorporation, international market development, and oncology product adoption amid a competitive molecular diagnostics landscape.